
A new stroke pill and two surgery rethinks lead four news stories
4 stories this week: preventing a second stroke, relapsed head and neck cancer, blood pressure pills on the morning of surgery and clot prevention after hip or knee replacement. What each result rests on and where it stops.
In 12,327 people after a stroke or TIA, a new pill added to antiplatelets cut repeat ischaemic strokes

On 9 November 2026 the US FDA approved Sunharbo (asundexian), the first factor XIa inhibitor, for adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, taken together with antiplatelet therapy. Factor XI is a clotting protein; people with naturally low levels have fewer ischaemic strokes, and that is the idea behind blocking it.
The approval rests on OCEANIC-STROKE, a phase 3 double-blind trial published in NEJM in April 2026. 12,327 patients were randomised within 72 hours of the event to asundexian or placebo on top of planned antiplatelet therapy. Ischaemic stroke occurred in 6.2% versus 8.4% (hazard ratio 0.74), and major bleeding in 1.9% versus 1.7%, a difference that was not significant. The trial was funded by Bayer, the manufacturer.
The FDA notes that major bleeding was higher in people older than 75 and during the first 90 days of treatment, and that gastrointestinal bleeding was more common. The drug is not approved for stroke prevention in atrial fibrillation, where clots form in the heart.
In 102 people with recurrent or metastatic head and neck cancer, a new form of amivantamab shrank tumours in 42%

On 5 November 2026 the FDA granted accelerated approval to Rybrevant Faspro (amivantamab with hyaluronidase) for adults with recurrent or metastatic squamous cell carcinoma of the head and neck that progressed after platinum chemotherapy and immunotherapy. HPV-associated cancer of the oropharynx is excluded from the indication. The sponsor is Janssen Biotech.
The basis is an open-label multicentre study of 102 patients with no comparison group. Tumours shrank or disappeared in 42% of them, and in 56% of those who responded the response lasted at least six months.
The approval is based on tumour response; the FDA requires confirmatory studies to verify and describe clinical benefit. The label warns of hypersensitivity and administration-related reactions, lung inflammation, skin and eye toxicity.
In 2,012 older adults, skipping the morning ACE inhibitor or ARB before surgery meant less low blood pressure under anaesthesia

On 11 November 2026 The BMJ published a double-blind trial from five hospitals in China, run from 2020 to 2023. 2,036 people aged 60 to 80 who took an ACE inhibitor or an angiotensin receptor blocker and were scheduled for non-cardiac surgery under general anaesthesia received either their usual pill or an identical placebo capsule on the morning of surgery.
2,012 completed the study. Low blood pressure around surgery (mean pressure below 65 mm Hg, or a fall of 30% or more that needed treatment) occurred in 31.2% of those who skipped the pill versus 45.5% of those who took it; drugs to raise blood pressure were needed in 28.5% versus 41.1%. Complications and deaths within 30 days did not differ significantly.
The result covers only these two drug classes, only people aged 60 to 80, only the dose on the morning of surgery and only hospitals in China. What to do with the morning dose is decided by the surgical and anaesthesia team.
In 15,317 people after hip or knee replacement, aspirin was not shown to be as good as blood thinners against clots

On 12 November 2026 NEJM published PEPPER, a comparative-effectiveness trial in which 18,883 people having elective hip or knee replacement were randomised to aspirin, warfarin or rivaroxaban for 30 days; 15,317 were included in the main per-protocol analysis. It was funded by the Patient-Centered Outcomes Research Institute.
Death or a symptomatic clot within six months occurred in 1.26% on aspirin, 1.23% on warfarin and 0.94% on rivaroxaban. Against the pre-set margin of 0.69 percentage points, aspirin was not non-inferior to rivaroxaban (difference 0.30 points, 95% CI −0.20 to 0.81) or to warfarin. The safety outcome, which combined bleeding, reoperation for wound problems and heart attack, occurred in 2.91%, 3.36% and 3.48%, and the two anticoagulants were not non-inferior to aspirin on it.
The authors conclude that aspirin was not non-inferior to rivaroxaban or warfarin for death or symptomatic clots, and that warfarin and rivaroxaban were not non-inferior to aspirin for safety.
This article is for information only and does not replace a consultation with a doctor. Nothing in it is a recommendation to start, stop or change treatment.
Sources
FDA approves first factor XIa inhibitor to help prevent stroke in certain adults at high risk. FDA press announcement, 9 November 2026. fda.gov
Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. PMID 41985132, doi:10.1056/NEJMoa2513880, NCT05686070
FDA grants accelerated approval to new treatment for head and neck squamous cell carcinoma. FDA press announcement, 5 November 2026. fda.gov
Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial. BMJ. 2026;395:e101087. PMID 43014822, doi:10.1136/bmj-2026-101087, ChiCTR2000039376
Prevention of Venous Thromboembolism after Total Hip or Knee Replacement. N Engl J Med. 2026;395(19):1896-1910. PMID 43013818, doi:10.1056/NEJMoa2602435, NCT02810704
Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.
Read next
ResearchMedicine and treatmentA tau antibody missed its main Alzheimer's score
For anyone following Alzheimer's research: what a phase 2 trial found on the score clinicians use to track daily function, and which questions that result leaves open.
ResearchMedicine and treatmentEarly TB treatment and an esophageal cancer drug — plus 2 stories
4 stories this week: severe pneumonia in infants with HIV, esophageal cancer after a first treatment line, blood pressure and memory in type 2 diabetes, and a heart-rhythm ablation. Each note names who was studied and where the result stops.
Digest · 4 stories
ResearchMedicine and treatmentThe busiest minute of the day lined up with fewer deaths
For a reader who already moves on ordinary days and still cannot tell which part of that day is worth a conversation with a doctor. Inside is a comparison of people as they already were, not a plan for the next week.